HMGB1 and metabolic dysfunction-associated steatohepatitis: Treatment with CNCs mitigates the severity of NASH by reducing expression of genes associated with the uptake of free fatty acids (CD36), liver inflammation (HMGB–1) and fibrosis (α–SMA).